title: Cutaneous side-effects of EGFR inhibitors and their management.
abstract: Epidermal growth factor receptor (EGFR) inhibitors are an increasingly important treatment option for metastasized cancer in patients. In addition to the pivotal role of EGFR in the development and progression of malignant tumors, EGFR is also important for proliferation and differentiation of the human epidermis and hair follicles. As a consequence, cutaneous side-effects are frequently observed during cancer therapy with EGFR inhibitors. During the first few weeks of treatment, acneiform eruptions are the earliest common side-effect. Xerosis and fissures are complications appearing in later treatment phases. Paronychia and alterations in hair growth are less common and generally seen after a longer period of treatment. We present an overview of the various cutaneous side-effects associated with EGFR inhibition and discuss their respective therapeutic options.
authors.affiliation: Department of Dermatology and Allergology, Ludwig-Maximilian-University of Munich, Munich, Germany.
authors.forename: L M
authors.initials: LM
authors.lastname: Ehmann
authors.forename: T
authors.initials: T
authors.lastname: Ruzicka
authors.forename: A
authors.initials: A
authors.lastname: Wollenberg
mesh_terms: D017486:Acneiform Eruptions / Q000139:chemically induced* / Q000188:drug therapy; D000284:Administration, Oral; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D024841:Fluoroquinolones / Q000627:therapeutic use; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy; D010304:Paronychia / Q000139:chemically induced* / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012176:Retinoids / Q000627:therapeutic use; D013684:Telangiectasis / Q000139:chemically induced
chemical_list: D000305:Adrenal Cortex Hormones; D000891:Anti-Infective Agents, Local; D002511:Cephalosporins; D024841:Fluoroquinolones; D047428:Protein Kinase Inhibitors; D012176:Retinoids; D066246:ErbB Receptors